HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA cosmetics division combination with CDER a possible scenario, Friedman suggests.

This article was originally published in The Rose Sheet

Executive Summary

FDA COSMETICS DIVISION COMBINATION WITH CDER COULD BE POSSIBLE as one of many scenarios for making better use of narrower agency resources by combining employees from the Office of Cosmetics & Colors with "people with similar sorts of skills" in the Center for Drug Evaluation & Research, Lead Deputy Commissioner Michael Friedman, MD, suggested to a CDER seminar on FDA reform Nov. 5. Friedman made his remarks in response to a question concerning the future of offices or divisions at FDA "that don't have clearly defined regulatory powers such as cosmetics...but have increasing impact on the consumer."
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel